Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies

NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply Tavros’ functional genomic discovery platform to develop next generation targeted small molecule drug candidates, initially to expand Zentalis’ oncology pipeline.